115621-54-0

Basic information

• Product Name: 3-(4-fluorophenyl)-2-butenoic acid ethyl ester
• Synonyms: 3-(4-fluorophenyl)-2-butenoic acid ethyl ester
• CAS NO: 115621-54-0
• Molecular Weight: 208.232
• Mol File: 115621-54-0.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: 3-(4-fluorophenyl)-2-butenoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-fluorophenyl)-2-butenoic acid ethyl ester(115621-54-0)
• EPA Substance Registry System: 3-(4-fluorophenyl)-2-butenoic acid ethyl ester(115621-54-0)

Safety Data

• Hazardous Substances Data: 115621-54-0(Hazardous Substances Data)

Upstream product

• 21133-97-1 ethyl 3-(4-fluorophenyl)-3-hydroxybutanoate 
• 688-49-3 ethyl (diethoxyphosphino)acetate 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 

Downstream Products

• 115653-71-9 C₁₂H₁₂BrFO₂ 
• 894421-53-5 (Z)-4-bromo-3-(4-fluorophenyl)-2-butenoic acid ethyl ester 
• 894421-66-0 (E)-4-cyano-3-(4-fluorophenyl)-2-butenoic acid ethyl ester 
• 1286204-37-2 (S)-ethyl 3-(p-fluorophenyl)butanoate 
• 148183-94-2 C₁₀H₁₁FO 
• 132533-08-5 (E)-3-(4-fluorophenyl)but-2-en-1-ol 

Relevant articles and documents

SELECTIVE ANDROGEN RECEPTOR COVALENT ANTAGONISTS (SARCAS) AND METHODS OF USE THEREOF

This invention relates to selective androgen receptor covalent antagonists, synthetic intermediates and by-products, and related compounds, and compositions comprising the same, and uses thereof in treating androgen receptor dependent diseases and conditions such as hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR.

Catalytic Asymmetric Transfer Hydrogenation of trans-Chalcone Derivatives Using BINOL-derived Boro-phosphates

Chiral phosphoric-acid-catalyzed asymmetric reductions of trans-chalcones have been investigated in this work. A BINOL-derived boro-phosphate-catalyzed asymmetric transfer hydrogenation of the carbon-carbon double bond of trans-chalcone derivatives employing borane as a hydride source was realized. This methodology provides a convenient procedure to access chiral dihydrochalone derivatives in high yields and with high enantioselectivities under mild conditions.

Dihydropyrrolones as bacterial quorum sensing inhibitors

Bacteria regulate their pathogenicity and biofilm formation through quorum sensing (QS), which is an intercellular communication system mediated by the binding of signaling molecules to QS receptors such as LasR. In this study, a range of dihydropyrrolone (DHP) analogues were synthesized via the lactone-lactam conversion of lactone intermediates. The synthesized compounds were tested for their ability to inhibit QS, biofilm formation and bacterial growth of Pseudomonas aeruginosa. The compounds were also docked into a LasR crystal structure to rationalize the observed structure-activity relationships. The most active compound identified in this study was compound 9i, which showed 63.1% QS inhibition of at 31.25 μM and 60% biofilm reduction at 250 μM with only moderate toxicity towards bacterial cell growth.